PDF(Pubmed)
Abstract：
The development of new treatment strategies to improve the prognosis of mucosal malignant melanoma of the head and neck (MMHN) after carbon ion radiotherapy (CIRT) is essential because of the risk of distant metastases. Therefore, our objective was to evaluate the outcomes of immune checkpoint inhibitor (ICI) treatment to justify its inclusion in the regimen after CIRT. Thirty-four patients who received CIRT as an initial treatment were included in the analysis and stratified into three groups: those who did not receive ICIs (Group A), those who received ICIs after recurrence or metastasis (Group B), and those who received ICIs as adjuvant therapy after CIRT (Group C). In total, 62% of the patients (n = 21) received ICIs. The 2-year local control and overall survival (OS) rates for all patients were 90.0% and 66.8%, respectively. The 2-year OS rates for patients in Groups A, B, and C were 50.8%, 66.7%, and 100%, respectively. No significant differences were observed between Groups A and B (p = 0.192) and Groups B and C (p = 0.112). However, a significant difference was confirmed between Groups A and C (p = 0.017). Adjuvant therapy following CIRT for MMHN may be a promising treatment modality that can extend patient survival.
摘要：
由于存在远处转移的风险，因此开发新的治疗策略以改善碳离子放疗（CIRT）后头颈部粘膜恶性黑色素瘤（MMHN）的预后至关重要。因此,我们的目的是评估免疫检查点抑制剂(ICI)治疗的结局,以证明其纳入CIRT后的治疗方案的合理性.将34例接受CIRT作为初始治疗的患者纳入分析，并分为三组：未接受ICIs的患者（A组），复发或转移后接受ICIs的患者（B组），以及在CIRT后接受ICIs作为辅助治疗的患者（C组）。总的来说,62%的患者(n=21)接受了ICIs。所有患者的2年局部控制率和总生存率(OS)分别为90.0%和66.8%,分别。A组患者的2年OS率，B,C为50.8%,66.7%,100%,分别。在A组和B组(p=0.192)与B组和C组(p=0.112)之间没有观察到显著差异。然而,A组和C组之间存在显著差异(p=0.017).MMHN的CIRT辅助治疗可能是一种有希望的治疗方式，可以延长患者的生存期。
